Cambridge, UK - 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, announces its unaudited half-year results for the six months ended 30 June 2026 ('H1 2026').
Operational and Commercial Highlights (including post period end)
New leadership team driving the Group's next phase of growth
Qualified new business pipeline of GBP63 million, up six-fold since Q3 2025, reflecting strong momentum in the business and the impact of new commercial team; pipeline demonstrates substantial demand and underpins future growth in 2027 and beyond
Secured clinical supply agreement to support Phase 2 clinical trial reflects increased adoption of synthetic DNA for clinical stage assets
Signed a strategic collaboration and marketing agreement with Genezen, a best-in-class viral vector CDMO; 4basebio selected as partner for excellent quality, reliability and safety
Commercial launch of innovative new offerings including single-stranded DNA (ssDNA) platform, and expanded NDA offering to enable high capacity, fast turnaround time DNA for personalised cancer vaccines (PCV)
Announced today, extension of existing relationship with Tier 1 pharmaceutical customer to include new modality, supporting its Phase 1 cell therapy programme with HQ opNDA
Financial Highlights
Sales orders for H1 2026 of GBP1.2 million, a 210% increase compared to H1 2025 sales orders (GBP0.4 million)
Revenue for H1 2026 of GBP0.3 million (H1 2025: GBP1.2 million), reflecting project delays due to general market headwinds that are now starting to ease, and a strong prior year comparator where revenues were derived from a single large clinical pharma contract
Cash balances of GBP14.1 million at period end (31 December 2025: GBP17.8 million) following EUR7 million drawdown under the 2Invest AG loan facility, providing a cash runway into late 2027
Loss for the period of GBP8.9 million (H1 2025 loss: GBP7.8 million) reflecting strategic investments in technology, manufacturing and commercial capability and deferrals of project revenues into H2 2026 and 2027
Net cash outflow from operating activities of GBP8.4 million (H1 2025: GBP8.2 million)
Outlook
Substantial and growing pipeline coupled with sizeable market opportunity for synthetic DNA underpins the Group's expected future growth
Sales orders executed to the date of this report of GBP1.4 million (including previously announced Phase II clinical supply agreement and today's announced extended relationship with a Tier 1 pharma) provide visibility over revenue of GBP1.2 million to be recognised over the next 12 months
HQ and GMP orders in late-stage contracting along with multiple well-progressed HQ and GMP opportunities expected to significantly increase revenue recognition in H2 2026 and 2027
With significant anticipated revenue growth and expected reduction in operating expenses following a period of strategic investment, the Group expects net cash outflows from operations to reduce in H2 2026 and also into 2027
Commenting on the interim results, Dr Amy Walker, CEO, said 'Following our investment into operational and commercial infrastructure in 2025, H1 2026 was a period of strong commercial momentum which positions us well to deliver future growth. I strongly believe that our differentiated technology and strengthened commercial capability will allow us to benefit from the expected growth in advanced therapies. Our enhanced commercial capabilities and team are reflected by a six-fold growth in our qualified pipeline and we enter H2 2026 with greatly enhanced visibility over future revenues.
We continue to receive consistently excellent feedback on our technology from our diversified customer base spanning biotech, pharma and CDMO across multiple modalities, and are encouraged by the continued adoption of our technology for clinical stage assets following our MHRA GMP certification, including a Phase 2 clinical trial. The long-term outlook for the synthetic DNA market and 4basebio remains exciting as clients increasingly pivot to a safer, quicker and high performance DNA source. We look forward to driving further commercial momentum with partners and clients through the remainder of 2026 and into 2027.'
Contact:
Dr. Amy Walker
Tel: +44 (0)12 2396 7943
Jo Turner
Tel: +44 (0)20 7213 0880
Jessica Hodgson
Tel: +44 (0)203 707 5700
(C) 2026 Electronic News Publishing, source ENP Newswire